CtDNA & NGS in Muscle-Invasive Bladder Cancer
Advancements and Controversies in Post-Operative Management of Muscle-Invasive Bladder Cancer
In the discourse around the management of muscle-invasive bladder cancer, particularly in older patients with significant medical comorbidities, healthcare providers face complex decision-making processes. The discussion revolves around post-operative strategies, the utility of genetic and molecular testing, and the utility of ctDNA assays in guiding treatment. What is your approach to post-operative management of an older patient with stage III muscle-invasive bladder cancer with medical comorbidities?
This is a pivotal question for healthcare providers navigating the intricacies of this disease.
Genetic and Molecular Testing
The role of genetic testing, specifically next-generation sequencing (NGS) and PD-L1 staining, is a contentious issue among oncology specialists. There remains a debate within the medical community about which patients should undergo these tests. If you see a patient like such as this, who has muscle-invasive bladder cancer would you always order NGS and PD-L1 staining, or is it more of a judgment call
based on a patient’s circumstances.
Dr. Ashish D. Dwary, expressed a conditional approach. Certain circumstances like this patient noted by Esther G. Chong, and intervention would not alter the management, especially in older patients with medical comorbidities. Because it wouldn’t change my management, in this particular setting.
she said in support of her argument.
Sumanta Pal acknowledged the challenge of managing muscle-invasive bladder cancer, particularly in the context of adjuvant chemotherapy. Previous clinical trials have not yielded satisfactory results, often due to biases in patient selection. Placebo-controlled trials provide new insights, but the decision to use adjuvant therapy remains nuanced. He said, I think part of the rationale for that is investigators had a lot of bias heading into these trials. They had a perspective on who should and who shouldn’t get adjunctive therapy, so these studies failed to accrue [patients].
Role of ctDNA Assays
Another critical aspect discussed is the use of circulating tumor DNA (ctDNA) assays. While some specialists use ctDNA testing to detect early recurrence, its role in guiding adjuvant therapy remains unclear. According to Dr. William E. Lee, The purpose of the Signatera test is to help document whether or not there’s early recurrence, more than dictating adjunctive treatment.
Having a colon for the professional members noted that the current assays, including Signatera, primarily help in detecting recurrence sooner than imaging techniques but suggested it may not necessarily improve long-term outcomes. Dr. Lee emphasized the role of Signatera in detecting recurrence more clearly. The most powerful role is going to be if it has a predictive role for immunotherapy. Having a bespoke assay, which analyzes a dozen or more genes
located at baseline.
are patient-specific to monitor cancer metabolites through ctDNA. The clinical significance of these findings is still an area of ongoing research. Recent studies, such as the one by Dr. Laliotis et al. 2023 review suggest that ctDNA could predict outcomes and complete pathological responses in bladder cancer patients, potentially guiding selective bladder preservation strategies. however, future trials will determine its practical utility in routine clinical settings, integrating ctDNA with immunotherapy based scientific evidence.
Future research is essential to determine the true value of ctDNA assays in predicting recurrence and guiding treatment decisions. Currently, the most valuable use of ctDNA may be in de-escalating or escalating therapy when integrated with other clinical parameters. Recent trials will play a crucial role in determining ctDNA’s future in clinical practice. Among these, the upcoming trial through the Alliance for Clinical Trials in Oncology is noteworthy. This study will look at allocating adjuvant nivolumab based on ctDNA and decide on nivolumab placement or list the ctDNA population in treatment for immunotherapy. Pal acknowledged, I think the ctDNA tests that we’re using for minimal residual disease are ultimately going to be most useful if we can use them in the context of de-escalating or escalating therapy.
Conclusion and Future Directions
The management of muscle-invasive bladder cancer in older patients with significant comorbidities requires a multidisciplinary approach. Future trials and advancing technologies such as ctDNA assays will need to conduct practical experimentations in different health contexts to redirect all resourceful findings in azonal settings to pioneer a comprehensive and effective treatment plan to design a balanced treatment for muscle-invasive bladder patients. Practitioners must carefully weigh the benefits and limitations of genetic and ctDNA tests, using them judiciously to enhance patient outcomes.
As the field continues to evolve, staying informed about the latest research and clinical trials will be crucial for healthcare providers navigating the complexities of muscle-invasive bladder cancer.
Advancements and Controversies in Post-Operative Management of Muscle-Invasive Bladder Cancer
Frequently Searched Q&A
1. What is the approach to post-operative management of an older patient with stage III muscle-invasive bladder cancer and medical comorbidities?
Answer:
- Multidisciplinary Approach: Management begins with a multidisciplinary team to consider all patient-specific factors, including comorbidities.
- Clinical Judgement: Decisions are highly individualized, frequently enough weighing the risks vs. benefits of intensive treatments like chemotherapy.
- Focus on Quality of Life: Treatment is typically tailored to balance efficacy while minimizing adverse effects,focusing on maintaining the quality of life.
2. Should genetic testing, like next-generation sequencing (NGS) and PD-L1 staining, be conducted for all muscle-invasive bladder cancer patients?
Answer:
- Contextual Testing: Dr.Ashish D. Dwary suggests a conditional approach where these tests are not ordered routinely but rather based on specific clinical circumstances.
- Clinical Impact Assessment: If testing doesn’t alter treatment plans, especially in older patients with comorbidities, it may be deemed unnecessary.
- Tailored Decisions: Decisions to order these tests are made based on potential to influence treatment strategies, particularly considering new therapies like immunotherapy.
3. How relevant is adjuvant chemotherapy in managing muscle-invasive bladder cancer, particularly post-surgery?
Answer:
- Historical Challenges: Past clinical trials have shown mixed results, often influenced by selection biases, as noted by specialists like Sumanta Pal.
- Nuanced Decisions: Although adjuvant chemotherapy can be beneficial, its use is nuanced, considering patient health, tumor characteristics, and potential therapy-related side effects.
- Emerging Therapies: New data and clinical trials are continuously evolving the use of adjuvant therapies, including targeted treatments like nivolumab based on molecular profiling.
4. What is the role of ctDNA assays in post-operative management?
Answer:
- Early Recurrence Detection: Tests like the Signatera assay are used to detect recurrence sooner than customary imaging, though its impact on long-term outcomes is still being studied.
- De-escalation and Escalation: ctDNA may guide therapy adjustment, assisting in decisions to escalate or de-escalate treatment based on recurrence risk.
- Future Utility: Ongoing trials are examining the potential for ctDNA to predict outcomes and tailor immunotherapy, supporting a more personalized treatment approach.
5. What future directions are anticipated in the management of muscle-invasive bladder cancer?
Answer:
- Integrative Approaches: Continued integration of genetic testing and ctDNA assays with clinical parameters to tailor more personalized treatment strategies.
- Ongoing Research: Future studies, particularly those funded by alliances such as the Alliance for Clinical Trials in Oncology, will uncover more about ctDNA’s role in treatment, supporting adaptive therapy decisions.
- Education and Updates: Healthcare providers will benefit from staying informed about emerging research and clinical trials to navigate complexities and offer the most informed care.
Conclusion
The management of muscle-invasive bladder cancer, especially in older patients with comorbidities, requires careful consideration of the latest evidence and tailored decision-making. As technologies and therapies advance, integration of ctDNA assays and nuanced use of genetic testing and adjuvant therapies will become crucial in offering optimal patient-specific care.
References
- Dyskjot L, Laliotis G, Nordentoft I, et al. Utility of ctDNA in predicting outcome and pathological complete response in patients with bladder cancer as a guide for selective bladder preservation strategies. J Clin Oncol. 2023;41(suppl 6):563. doi: 10.1200/JCO.2023.41.6_suppl.563
This article consolidates the current knowledge and controversies regarding post-operative management of muscle-invasive bladder cancer, emphasizing expert insights and the potential of emerging technologies while remaining evergreen by avoiding time-specific references.